tabalumab

Tabalumab is a fully human IgG4 monoclonal antibody that targets and neutralizes both soluble and membrane-bound B-cell activating factor (BAFF), a cytokine critical for B-cell survival, proliferation, and differentiation. By inhibiting BAFF, tabalumab reduces the activity and survival of B-cells, which are implicated in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Developed by Eli Lilly, tabalumab was investigated primarily for SLE and RA but also explored in other conditions like multiple myeloma, multiple sclerosis, renal failure, chronic kidney disease, connective tissue disease, and autoimmune diseases. Despite promising biological activity in early trials for RA and SLE, phase 3 studies failed to meet primary efficacy endpoints. As a result, development was discontinued across all indications[1][2][3][4][5][6][7].

Other names

tabalumabAnti-BAFF monoclonal antibodyAnti-BAFF MAb